A. Melnyk

457 total citations
9 papers, 361 citations indexed

About

A. Melnyk is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, A. Melnyk has authored 9 papers receiving a total of 361 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 2 papers in Surgery. Recurrent topics in A. Melnyk's work include HER2/EGFR in Cancer Research (3 papers), Cancer Treatment and Pharmacology (3 papers) and Advanced Sensor and Energy Harvesting Materials (1 paper). A. Melnyk is often cited by papers focused on HER2/EGFR in Cancer Research (3 papers), Cancer Treatment and Pharmacology (3 papers) and Advanced Sensor and Energy Harvesting Materials (1 paper). A. Melnyk collaborates with scholars based in United States, France and Canada. A. Melnyk's co-authors include Maria Alma Rodriguez, William Pugh, Gisela L. Schulz, Denis Andrienko, Amer Hamidi‐Sakr, Florian S. U. Fischer, Sabine Ludwigs, Martin Brinkmann, Daniel Trefz and Ramaswamy Govindan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

A. Melnyk

9 papers receiving 358 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Melnyk United States	7	196	191	87	77	63	9	361
Megumi Hirabayashi Japan	13	147 0.8×	75 0.4×	72 0.8×	141 1.8×	49 0.8×	30	416
D Dantchev France	10	89 0.5×	160 0.8×	33 0.4×	117 1.5×	35 0.6×	28	388
Daciana Antal France	6	169 0.9×	190 1.0×	60 0.7×	59 0.8×	16 0.3×	9	410
Aleš Obr Czechia	8	366 1.9×	384 2.0×	26 0.3×	74 1.0×	42 0.7×	21	483
Pim Mutsaers Netherlands	8	185 0.9×	270 1.4×	14 0.2×	59 0.8×	34 0.5×	30	371
Huang Huang Canada	8	245 1.3×	343 1.8×	18 0.2×	93 1.2×	26 0.4×	14	413
Andy Chen United States	9	114 0.6×	206 1.1×	14 0.2×	40 0.5×	25 0.4×	20	269
Yajuan Qin United States	5	289 1.5×	398 2.1×	12 0.1×	72 0.9×	34 0.5×	8	448
Kim de Lange Netherlands	10	35 0.2×	218 1.1×	113 1.3×	136 1.8×	5 0.1×	18	435
Athanasios Galanopoulos Greece	10	46 0.2×	159 0.8×	57 0.7×	88 1.1×	6 0.1×	40	492

Countries citing papers authored by A. Melnyk

Since Specialization

Citations

This map shows the geographic impact of A. Melnyk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Melnyk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Melnyk more than expected).

Fields of papers citing papers by A. Melnyk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Melnyk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Melnyk. The network helps show where A. Melnyk may publish in the future.

Co-authorship network of co-authors of A. Melnyk

This figure shows the co-authorship network connecting the top 25 collaborators of A. Melnyk. A scholar is included among the top collaborators of A. Melnyk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Melnyk. A. Melnyk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Lee, Eric, Oladapo Yeku, Ira Winer, et al.. (2024). 719MO A phase I/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer. Annals of Oncology. 35. S550–S550. 3 indexed citations

Schulz, Gisela L., Florian S. U. Fischer, Daniel Trefz, et al.. (2017). The PCPDTBT Family: Correlations between Chemical Structure, Polymorphism, and Device Performance. Macromolecules. 50(4). 1402–1414. 51 indexed citations

George, Timothy, Stefan Krüger, Anne Favret, et al.. (2012). Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study. Annals of Oncology. 23(10). 2599–2605. 6 indexed citations

Jalal, Shadia I., A. Melnyk, Donald Richards, et al.. (2011). Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Annals of Oncology. 23(7). 1730–1738. 58 indexed citations

Yardley, Denise A., Isabelle Ray‐Coquard, Bohuslav Melichar, et al.. (2009). Ridaforolimus (AP23573; MK-8669) in Combination with Trastuzumab for Patients with HER2-Positive Trastuzumab-Refractory Metastatic Breast Cancer: A Multicenter Phase 2 Clinical Trial.. Cancer Research. 69(24_Supplement). 3091–3091. 17 indexed citations

Melnyk, A., et al.. (1997). Evaluation of the Revised European-American Lymphoma Classification Confirms the Clinical Relevance of Immunophenotype in 560 Cases of Aggressive Non-Hodgkin's Lymphoma. Blood. 89(12). 4514–4520. 184 indexed citations

Melnyk, A., et al.. (1996). Ukrain treatment in a patient with non-seminomatous germ-cell tumour of testis (case report).. PubMed. 22(3-5). 263–5. 1 indexed citations

Melnyk, A., et al.. (1995). Lethal tracheal dissolution during treatment for thyroid lymphoma. Thorax. 50(10). 1120–1121. 7 indexed citations

Younes, Anas, A H Sarris, A. Melnyk, et al.. (1995). Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 13(3). 583–587. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact